[1]	Cheng S, He J, Han Y, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021[J]. Europace, 2024, 26(7):euae195.DOI:10.1093/europace/euae195. Cited in this article [1]

[2]	Chugh SS, Roth GA, Gillum RF, et al. Global burden of atrial fibrillation in developed and developing nations[J]. Glob Heart, 2014, 9(1):113-119.DOI:10.1016/j.gheart.2014.01.004. Cited in this article [1]

[3]

Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran,rivaroxaban,apixaban) versus no treatment in a ‘real world’ atrial fibrillation population:a modelling analysis based on a nationwide cohort study[J]. Thromb Haemost, 2012, 107(3):584-589.DOI:10.1160/TH11-11-0784. Cited in this article [1]

[4]	Potpara TS, Mujovic N, Lip GYH. Meeting the unmet needs to improve management and outcomes of patients with atrial fibrillation:fitting global solutions to local settings[J]. Pol Arch Intern Med, 2019, 129(9):574-576.DOI:10.20452/pamw.14996. Cited in this article [1]

[5]	Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10):883-891.DOI:10.1056/NEJMoa1009638. Cited in this article [2]

[6]	Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.DOI:10.1056/NEJMoa1107039. Cited in this article [2]

[7]	Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22):2093-2104.DOI:10.1056/NEJMoa1310907. Cited in this article [2]

[8]

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2024, 149(1):e1-e156.DOI:10.1161/CIR.0000000000001193. Cited in this article [1]

[9]	Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2024, 45(36):3314-3414.DOI:10.1093/eurheartj/ehae176. Cited in this article [1]

[10]	Ma CS, Wu SL, Liu SW, et al. Chinese guidelines for the diagnosis and management of atrial fibrillation[J]. J Geriatr Cardiol, 2024, 21(3):251-314.DOI:10.26599/1671-5411.2024.03.009. Cited in this article [1]

[11]	Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921):955-962.DOI:10.1016/S0140-6736(13)62343-0. Cited in this article [2]

[12]	Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.DOI:10.1056/NEJMoa0905561. Cited in this article [1]

[13]	Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation[J]. J Am Coll Cardiol, 2007, 50(4):309-315.DOI:10.1016/j.jacc.2007.01.098. Cited in this article [2]

[14]	Klatsky AL, Friedman GD, Sidney S, et al. Risk of hemorrhagic stroke in Asian American ethnic groups[J]. Neuroepidemiology, 2005, 25(1):26-31.DOI:10.1159/000085310. Cited in this article [1]

[15]	Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage:The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study[J]. J Am Coll Cardiol, 2011, 58(4):395-401.DOI:10.1016/j.jacc.2011.03.031. Cited in this article [1]

[16]	Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey[J]. Chest, 2010, 138(5):1093-1100.DOI:10.1378/chest.10-0134. Cited in this article [2]

[17]	Benz AP, Hijazi Z, Lindback J, et al. Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation[J]. Circulation, 2021, 143(19):1863-1873.DOI:10.1161/CIRCULATIONAHA.120.053100. Cited in this article [1]

[18]	Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage:results from the National Registry of Atrial Fibrillation (NRAF)[J]. Am Heart J, 2006, 151(3):713-719.DOI:10.1016/j.ahj.2005.04.017. Cited in this article [1]

[19]

Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC Score:a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants[J]. Circulation, 2023, 148(12):936-946.DOI:10.1161/CIRCULATIONAHA.123.064556. Cited in this article [1]

[20]	Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients[J]. Chest, 2006, 130(5):1390-1396.DOI:10.1378/chest.130.5.1390. Cited in this article [1]

[21]

Fox K, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation:an integrated GARFIELD-AF tool for the prediction of mortality,stroke and bleed in patients with and without anticoagulation[J]. BMJ Open, 2017, 7(12):e017157.DOI:10.1136/bmjopen-2017-017157. Cited in this article [1]

[22]	O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score:a simple bedside score to assess bleeding risk in atrial fibrillation[J]. Eur Heart J, 2015, 36(46):3258-3264.DOI:10.1093/eurheartj/ehv476. Cited in this article [1]

[23]	Chang G, Xie Q, Ma L, et al. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation:a network meta-analysis[J]. J Thromb Haemost, 2020, 18(4):791-801.DOI:10.1111/jth.14692.

[24]	Singer DE. Methodologic problems in the assessment of bleed scores[J]. J Am Coll Cardiol, 2013, 61(4):481.DOI:10.1016/j.jacc.2012.09.052.

[25]	丁聪聪, 詹碧鸣, 周伟, 等. 四种评分系统对服用达比加群的心房颤动患者出血风险的预测价值比较[J]. 中华心血管病杂志, 2020, 48(9):748-752.DOI:10.3760/cma.j.cn112148-20200617-00492.

[26]

Proietti M, Romiti GF, Vitolo M, et al. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants:a report from the ESC-EHRA EORP-AF General Long-Term Registry[J]. Eur Heart J Qual Care Clin Outcomes, 2022, 8(7):778-786.DOI:10.1093/ehjqcco/qcab069.

[27]

Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation:the HAS-BLED (Hypertension,Abnormal Renal/Liver Function,Stroke,Bleeding History or Predisposition,Labile INR,Elderly,Drugs/Alcohol Concomitantly) score[J]. J Am Coll Cardiol, 2011, 57(2):173-180.DOI:10.1016/j.jacc.2010.09.024.

[28]

Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in ’real world’ patients with atrial fibrillation:comparison of the HAS-BLED and ABC-Bleeding risk scores.The Murcia Atrial Fibrillation Project[J]. Thromb Haemost, 2017, 117(10):1848-1858.DOI:10.1160/TH17-07-0478.

[29]	Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC Scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation, 2019, 139(6):760-771.DOI:10.1161/CIRCULATIONAHA.118.038312.

[30]

Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES,ATRIA,and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation:the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study[J]. J Am Coll Cardiol, 2012, 60(9):861-867.DOI:10.1016/j.jacc.2012.06.019.

[31]	Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, et al. Predicting bleeding events in anticoagulated patients with atrial fibrillation:a comparison between the HAS-BLED and GARFIELD-AF bleeding scores[J]. J Am Heart Assoc, 2018, 7(18):e009766.DOI:10.1161/JAHA.118.009766.

[32]	Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age,biomarkers,clinical history)-bleeding risk score for patients with atrial fibrillation:a derivation and validation study[J]. Lancet, 2016, 387(10035):2302-2311.DOI:10.1016/S0140-6736(16)00741-8. Cited in this article [1]

[33]	Donze J, Rodondi N, Waeber G, et al. Scores to predict major bleeding risk during oral anticoagulation therapy:a prospective validation study[J]. Am J Med, 2012, 125(11):1095-1102.DOI:10.1016/j.amjmed.2012.04.005.

[34]	Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation:insights from the ARISTOTLE trial[J]. Eur Heart J, 2012, 33(22):2821-2830.DOI:10.1093/eurheartj/ehs274. Cited in this article [1]

[35]	Oyama K, Giugliano RP, Berg DD, et al. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial[J]. Eur Heart J, 2021, 42(17):1698-1706.DOI:10.1093/eurheartj/ehab141. Cited in this article [1]

[36]	Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation[J]. Am Heart J, 2015, 170(6):1151-1160.DOI:10.1016/j.ahj.2015.09.018. Cited in this article [1]

[37]	Rivera-Caravaca JM, Marin F, Vilchez JA, et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores[J]. Stroke, 2019, 50(6):1372-1379.DOI:10.1161/STROKEAHA.118.024305. Cited in this article [1]

[38]

Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation:the prospective,multicentre observational PREvention oF thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF)[J]. BMJ Open, 2019, 9(3):e022478.DOI:10.1136/bmjopen-2018-022478. Cited in this article [1]

[39]	Sakuma I, Uchiyama S, Atarashi H, et al. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban:the EXPAND Study sub-analysis[J]. Heart Vessels, 2019, 34(11):1839-1851.DOI:10.1007/s00380-019-01425-x. Cited in this article [1]

[40]	Banerjee A, Fauchier L, Vourc’HP, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation:the Loire Valley Atrial Fibrillation Project[J]. Chest, 2014, 145(6):1370-1382.DOI:10.1378/chest.13-2103. Cited in this article [1]

[41]	石雨蒙, 周伟, 李明辉, 等. 服用达比加群的老年高血压伴非瓣膜性心房颤动患者估算肾小球滤过率与出血的相关性[J]. 中国循环杂志, 2020, 35(10):967-972.DOI:10.3969/j.issn.1000-3614.2020.10.005 Cited in this article [1]

[42]	Xiong Y, Hu L, Zhou W, et al. Association between the change in total bilirubin and risk of bleeding among patients with nonvalvular atrial fibrillation taking dabigatran[J]. Clin Appl Thromb Hemost, 2020,26:1146424392.DOI:10.1177/1076029620910808. Cited in this article [1]

[43]	Westenbrink BD, Alings M, Connolly SJ, et al. Anemia predicts thromboembolic events,bleeding complications and mortality in patients with atrial fibrillation:insights from the RE-LY trial[J]. J Thromb Haemost, 2015, 13(5):699-707.DOI:10.1111/jth.12874.

[44]	Weiss HJ, Lages B, Hoffmann T, et al. Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit—possible role of adenosine diphosphate[J]. Blood, 1996, 87(10):4214-4222.DOI:10.1182/blood.V87.10.4214.bloodjournal87104214.

[45]	Park J, Cha MJ, Choi YJ, et al. Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation[J]. Heart Rhythm, 2019, 16(2):197-203.DOI:10.1016/j.hrthm.2018.08.023.

[46]	Xiong Y, Zhou W, Li M, et al. Association between platelet count and the risk of bleeding among patients with nonvalvular atrial fibrillation taking dabigatran after radiofrequency ablation:a cohort study[J]. Cardiovasc Diagn Ther, 2020, 10(5):1175-1183.DOI:10.21037/cdt-20-645.

[47]	Zhou W, Wang T, Zhu L, et al. Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran:a real-world study[J]. Chin Med J (Engl), 2019, 132(18):2150-2156.DOI:10.1097/CM9.0000000000000423.

[48]	Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation:a systematic review[J]. QJM, 2007, 100(10):599-607.DOI:10.1093/qjmed/hcm076. Cited in this article [1]

[49]

Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation:an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial[J]. Circulation, 2011, 123(21):2363-2372.DOI:10.1161/CIRCULATIONAHA.110.004747. Cited in this article [1]

[50]	Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of Edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial[J]. J Am Heart Assoc, 2016, 5(5):e003432.DOI:10.1161/JAHA.116.003432. Cited in this article [1]

[51]	Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation[J]. Circulation, 2016, 133(4):352-360.DOI:10.1161/CIRCULATIONAHA.115.018544. Cited in this article [1]

[52]	Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation:observations from the ARISTOTLE trial[J]. Eur Heart J, 2014, 35(28):1864-1872.DOI:10.1093/eurheartj/ehu046. Cited in this article [1]

[53]

Essien UR, Chiswell K, Kaltenbach LA, et al. Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation:findings from the Get With The Guidelines-Atrial Fibrillation Registry[J]. JAMA Cardiol, 2022, 7(12):1207-1217.DOI:10.1001/jamacardio.2022.3704. Cited in this article [1]

[54]	Ayala C, Greenlund KJ, Croft JB, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States,1995-1998[J]. Am J Epidemiol, 2001, 154(11):1057-1063.DOI:10.1093/aje/154.11.1057. Cited in this article [1]

[55]	Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era[J]. Br J Haematol, 2011, 155(2):137-149.DOI:10.1111/j.1365-2141.2011.08826.x. Cited in this article [1]

[56]	Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight[J]. Circulation, 2019, 139(20):2292-2300.DOI:10.1161/CIRCULATIONAHA.118.037955. Cited in this article [1]

[57]	Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[J]. Circulation, 2013, 127(5):634-640.DOI:10.1161/CIRCULATIONAHA.112.115386. Cited in this article [1]

[58]	Chao TF, Chan YH, Chiang CE, et al. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk[J]. Eur Heart J Qual Care Clin Outcomes, 2022, 8(7):730-738.DOI:10.1093/ehjqcco/qcab076. Cited in this article [1]

[59]

Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation:executive summary[J]. Europace, 2018, 20(8):1231-1242.DOI:10.1093/europace/euy054. Cited in this article [1]

[60]	Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy:a population-based study in Rochester,Minnesota[J]. Mayo Clin Proc, 1995, 70(8):725-733.DOI:10.4065/70.8.725. Cited in this article [1]

[61]	Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation[J]. Blood Adv, 2018, 2(3):200-209.DOI:10.1182/bloodadvances.2017010694. Cited in this article [1]

[62]	Kodani E, Otsuka T, Tomita H, et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation:a subanalysis of the J-RHYTHM Registry[J]. J Am Heart Assoc, 2016, 5(9):e004075.DOI:10.1161/JAHA.116.004075. Cited in this article [1]

[63]	Kodani E, Inoue H, Atarashi H, et al. Impact of blood pressure visit-to-visit variability on adverse events in patients with nonvalvular atrial fibrillation:subanalysis of the J-RHYTHM Registry[J]. J Am Heart Assoc, 2021, 10(1):e018585.DOI:10.1161/JAHA.120.018585. Cited in this article [1]

[64]

Yu Y, Li M, Zhou W, et al. Diastolic blood pressure achieved at target systolic blood pressure (120-140 mmHg) and dabigatran-related bleeding in patients with nonvalvular atrial fibrillation:a real-world study[J]. Anatol J Cardiol, 2020, 24(4):267-273.DOI:10.14744/AnatolJCardiol.2020.11823. Cited in this article [1]

[65]	Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation[J]. N Engl J Med, 2019, 380(16):1509-1524.DOI:10.1056/NEJMoa1817083. Cited in this article [1]

[66]	Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375(25):2423-2434.DOI:10.1056/NEJMoa1611594. Cited in this article [1]

[67]	Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation:nationwide cohort study[J]. BMJ, 2015,351:h5876.DOI:10.1136/bmj.h5876. Cited in this article [1]

[68]	Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of direct oral anticoagulants:a systematic review[J]. J Pers Med, 2021, 11(1):37.DOI:10.3390/jpm11010037. Cited in this article [1]

[69]	Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace,2021, 23(10):1612-1676.DOI:10.1093/europace/euab065. Cited in this article [1]

[70]	Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding[J]. Circulation, 2013, 127(13):1404-1412.DOI:10.1161/CIRCULATIONAHA.112.001233. Cited in this article [1]

[71]	Ji Q, Zhang C, Xu Q, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation[J]. Br J Clin Pharmacol, 2021, 87(5):2247-2255.DOI:10.1111/bcp.14646. Cited in this article [1]

[72]	Sennesael AL, Larock AS, Douxfils J, et al. Rivaroxaban plasma levels in patients admitted for bleeding events:insights from a prospective study[J]. Thromb J, 2018,16:28.DOI:10.1186/s12959-018-0183-3. Cited in this article [1]

[73]	Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability[J]. Thromb Res, 2016, 145:24-26.DOI:10.1016/j.thromres.2016.07.005. Cited in this article [1]

[74]	Rosian AN, Iancu M, Trifa AP, et al. An Exploratory association analysis of ABCB(1) rs1045642 and ABCB(1) rs4148738 with non-major bleeding risk in atrial fibrillation patients treated with dabigatran or apixaban[J]. J Pers Med, 2020, 10(3):133.DOI:10.3390/jpm10030133. Cited in this article [1]

[75]

Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4,CYP3A5,ABCB1 gene polymorphisms on rivaroxaban pharmacokinetics in patients undergoing total hip and knee replacement surgery[J]. High Blood Press Cardiovasc Prev, 2019, 26(5):413-420.DOI:10.1007/s40292-019-00342-4. Cited in this article [1]

[76]	Nakagawa J, Kinjo T, Iizuka M, et al. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation[J]. Basic Clin Pharmacol Toxicol, 2021, 128(2):297-304.DOI:10.1111/bcpt.13488. Cited in this article [1]

[77]	Ueshima S, Hira D, Fujii R, et al. Impact of ABCB1,ABCG2,and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation[J]. Pharmacogenet Genomics, 2017, 27(9):329-336.DOI:10.1097/FPC.0000000000000294. Cited in this article [1]

[78]	Ueshima S, Hira D, Kimura Y, et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation[J]. Br J Clin Pharmacol, 2018, 84(6):1301-1312.DOI:10.1111/bcp.13561. Cited in this article [1]

[79]	Gulilat M, Keller D, Linton B, et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care[J]. J Thromb Thrombolysis, 2020, 49(2):294-303.DOI:10.1007/s11239-019-01962-2. Cited in this article [1]

[80]	Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke[J]. Pharmgenomics Pers Med, 2018, 11:43-49.DOI:10.2147/PGPM.S157111. Cited in this article [1]